Inogen (NASDAQ: SIEN) and Sientra (NASDAQ:SIEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Risk & Volatility

Inogen has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Sientra has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500.


This table compares Inogen and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inogen 10.39% 16.51% 13.48%
Sientra -131.16% -151.47% -58.22%

Insider and Institutional Ownership

96.5% of Inogen shares are owned by institutional investors. Comparatively, 89.2% of Sientra shares are owned by institutional investors. 5.3% of Inogen shares are owned by insiders. Comparatively, 31.0% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Inogen and Sientra, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen 0 1 5 0 2.83
Sientra 0 0 9 0 3.00

Inogen presently has a consensus price target of $238.80, suggesting a potential downside of 15.59%. Sientra has a consensus price target of $24.14, suggesting a potential downside of 1.78%. Given Sientra’s stronger consensus rating and higher probable upside, analysts plainly believe Sientra is more favorable than Inogen.

Valuation and Earnings

This table compares Inogen and Sientra’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inogen $249.44 million 24.22 $21.00 million $1.31 215.97
Sientra $36.54 million 19.12 -$64.02 million ($2.82) -8.72

Inogen has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.


Inogen beats Sientra on 10 of the 14 factors compared between the two stocks.

Inogen Company Profile

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Sientra Company Profile

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with's FREE daily email newsletter.